By Dr Jialing Lin

Conference Abstracts

Lin J; Pearson S; Greenfield J; Park KH; Havard A; Brieger D; Day R; Falster M; de Oliveira Costa J, 2023, 'Trends in the use of Cardiometabolic Medicines in Australia (2014-2022): Sodium-glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide-1 Analogues', in Trends in the use of Cardiometabolic Medicines in Australia (2014-2022): Sodium-glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide-1 Analogues, presented at Australian Diabetes Congress 2023

Lin J; Pearson S; Greenfield J; Park KH; Havard A; Brieger D; Day R; Falster M, 2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022)', in Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022), presented at 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2023

Lin J; Gong K; Ding S; Ding Y; Zhang M; Chen D; Zhang Z; Tang S, 2018, 'Comparison in the associations of office and ambulatory blood pressures with urinary microalbuminuria in community residents with hypertension', in Journal of Hypertension, Lippincott, Williams & Wilkins, Vol. 36, pp. e344 - e344, presented at 27th Scientific Meeting of the International Society of Hypertension, http://dx.doi.org/10.1097/01.hjh.0000549405.61251.8f

Lin J; Gong K; Ding S; Ding Y; Zhang M; Chen D; Zhang Z; Tang S, 2018, 'Utility of home blood pressure telemonitoring to evaluate early impaired renal function in rural community hypertensive residents: based on dose-response relationship in a cross-sectional study', in Journal of Hypertension, Lippincott, Williams & Wilkins, Vol. 36, pp. e344 - e344, presented at 27th Scientific Meeting of the International Society of Hypertension, http://dx.doi.org/10.1097/01.hjh.0000549406.12832.17

Back to profile page